论文部分内容阅读
目的探讨不同治疗模式下局限期小细胞肺癌患者的预后差异。方法回顾性分析48例局限期小细胞肺癌患者的临床资料,比较不同治疗模式下患者的中位生存期(median survival time,MST)、无进展生存期(progression free time,PFS)及不良反应发生率差异。结果综合治疗组(规范性化疗+同步放化疗+预防性脑放疗)患者MST显著优于不规范治疗组(P<0.05);规范性化疗组患者MST优于不规范性化疗组(P<0.05);同步放化疗组与序贯放化疗组患者MST比较差异无统计学意义(P=0.159);预防性脑放射组患者MST优于未行预防性脑放射组(P<0.05);综合治疗模式规范组患者PFS亦优于不规范组(P<0.05)。结论规范性综合治疗可显著提高局限期小细胞肺癌患者的MST和PFS。
Objective To investigate the prognosis of patients with small cell lung cancer under different treatment modalities. Methods The clinical data of 48 patients with small cell lung cancer were retrospectively analyzed. The median survival time (MST), progression free survival (PFS) and adverse reactions were compared among different treatment modalities. Rate difference. Results The MST was significantly superior to the non-canonical treatment group (P <0.05) in the comprehensive treatment group (normative chemotherapy + concurrent chemoradiotherapy + prophylactic brain radiation therapy); the MST in the normative chemotherapy group was superior to the non-canonical chemotherapy group ). There was no significant difference in the MST between the concurrent chemoradiotherapy group and the sequential radiochemotherapy group (P = 0.159). The MST in the preventive brain radiotherapy group was superior to that in the non-preventive brain radiotherapy group (P <0.05) PFS in model group was also better than that in non-standard group (P <0.05). Conclusion Normative comprehensive treatment can significantly improve the MST and PFS in patients with localized small cell lung cancer.